Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 13/20 | 0.37 |
| ▸ | FABP3 | P05413 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22289935 | 0.83 | FABP4 (0.35) | FABP4FABP3KDM4ENPC1ALDH1A1 | |
| SCHEMBL22289967 | 0.80 | ALDH1A1 (0.34) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL20674616 | 0.76 | FABP4 (0.43) | FABP4FABP3KDM4EALDH1A1MYC | |
| SCHEMBL12748792 | 0.76 | AKR1C3 (0.55) | ALDH1A1KMT2AHSD17B10L3MBTL1 | |
| SCHEMBL20631141 | 0.74 | FABP4 (0.39) | FABP4FABP3KDM4EKMT2AHSD17B10 | |
| SCHEMBL22289970 | 0.67 | MYC (0.41) | FABP4KDM4EALDH1A1KMT2AMYC | |
| SCHEMBL22300135 | 0.67 | FABP4 (0.34) | FABP4FABP3MYCPOLB | |
| SCHEMBL29248871 | 0.65 | BRD4 (0.38) | FABP4KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL6674814 | 0.62 | AKR1C3 (0.62) | FABP4FABP3ALDH1A1KMT2APOLB | |
| SCHEMBL20631138 | 0.62 | GRIA2 (0.35) | FABP4FABP3KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2020160100-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | FABP4 1716/4885FABP3 3443/4885KDM4E 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.